(Q35078787)

English

Assessment of HER2 status in breast cancer: overall positivity rate and accuracy by fluorescence in situ hybridization and immunohistochemistry in a single institution over 12 years: a quality control study

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

Assessment of HER2 status in breast cancer: overall positivity rate and accuracy by fluorescence in situ hybridization and immunohistochemistry in a single institution over 12 years: a quality control study (English)

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

quality control

0 references

immunohistochemistry

1 reference

based on heuristic

inferred from title

2

object named as

Aurelia Noske

0 references

Zsuzsanna Varga

1

object named as

Zsuzsanna Varga

0 references

5

object named as

Holger Moch

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

author name string

Constanze Ramach

3

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

Barbara Padberg

4

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

language of work or name

0 references

publication date

30 December 2013

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

13

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

615

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

describes a project that uses

fluorescence in situ hybridization

1 reference

based on heuristic

inferred from title

https://scigraph.springernature.com/pub.10.1186/1471-2407-13-615

0 references

Economic evaluations of trastuzumab in HER2-positive metastatic breast cancer: a systematic review and critique

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3879657

8 July 2018

Assessing HER2 amplification in breast cancer: findings from the Australian In Situ Hybridization Program

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3879657

8 July 2018

Internal Quality Assurance Program for ERBB2 (HER2) Testing Improves the Selection of Breast Cancer Patients for Treatment with Trastuzumab.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3879657

8 July 2018

Quality assessment of HER2 testing by monitoring of positivity rates

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3879657

8 July 2018

Current technologies for HER2 testing in breast cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3879657

8 July 2018

Chromosome 17 polysomy without HER2 amplification does not predict response to lapatinib in metastatic breast cancer--letter

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3879657

8 July 2018

The impact of pre-analytical processing on staining quality for H&E, dual hapten, dual color in situ hybridization and fluorescent in situ hybridization assays

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3879657

8 July 2018

Guidelines for human epidermal growth factor receptor 2 testing: biologic and methodologic considerations

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3879657

8 July 2018

External quality assurance of HER2 FISH and ISH testing: three years of the UK national external quality assurance scheme

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3879657

8 July 2018

What causes discrepancies in HER2 testing for breast cancer? A Japanese ring study in conjunction with the global standard

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3879657

8 July 2018

Current issues in ER and HER2 testing by IHC in breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3879657

8 July 2018

National HER2 proficiency test results using standardized quantitative controls: characterization of laboratory failures

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3879657

8 July 2018

Fluorescence in situ hybridization (FISH) as primary methodology for the assessment of HER2 Status in adenocarcinoma of the breast: a single institution experience

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3879657

8 July 2018

American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3879657

8 July 2018

Assessment of the HER2 status in breast cancer by fluorescence in situ hybridization: a technical review with interpretive guidelines

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3879657

8 July 2018

Predicting the HER2 status of breast cancer from basic histopathology data: an analysis of 1500 breast cancers as part of the HER2000 International Study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3879657

8 July 2018

The clinical evaluation of HER-2 status: which test to use?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3879657

8 July 2018

Current perspectives on HER2 testing: a review of national testing guidelines

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3879657

8 July 2018

Current status of HER2 testing: caught between a rock and a hard place

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3879657

8 July 2018

Recommendations for HER2 testing in the UK.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3879657

8 July 2018

Her-2/neu analysis in archival tissue samples of human breast cancer: comparison of immunohistochemistry and fluorescence in situ hybridization

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3879657

8 July 2018

Reliability of core needle biopsy for determining ER and HER2 status in breast cancer.

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-13-615

21 January 2018

HER2-testing in 538 consecutive breast cancer cases using FISH and immunohistochemistry.

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-13-615

21 January 2018

Human epidermal growth factor receptor 2 expression in early breast cancer patients: a Swiss cost-effectiveness analysis of different predictive assay strategies.

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-13-615

21 January 2018

High concordance between HercepTest immunohistochemistry and ERBB2 fluorescence in situ hybridization before and after implementation of American Society of Clinical Oncology/College of American Pathology 2007 guidelines

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-13-615

21 January 2018

Effects of the change in cutoff values for human epidermal growth factor receptor 2 status by immunohistochemistry and fluorescence in situ hybridization: a study comparing conventional brightfield microscopy, image analysis-assisted microscopy, and

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-13-615

21 January 2018

HER2 ASCO guidelines. The answer to everything?

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-13-615

21 January 2018

Effect of ischemic time, fixation time, and fixative type on HER2/neu immunohistochemical and fluorescence in situ hybridization results in breast cancer.

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-13-615

21 January 2018

Evaluating HER2 amplification and overexpression in breast cancer.

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-13-615

21 January 2018

Accuracy of HER2 status determination on breast core-needle biopsies (immunohistochemistry, FISH, CISH and SISH vs FISH).

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-13-615

21 January 2018

Standardization of HER2 testing: results of an international proficiency-testing ring study.

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-13-615

21 January 2018

Immunohistochemistry validation procedures and practices: a College of American Pathologists survey of 727 laboratories.

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-13-615

21 January 2018

Effectiveness of organised versus opportunistic mammography screening

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-13-615

21 January 2018

Genetic heterogeneity in HER2 testing in breast cancer: panel summary and guidelines

1 reference

https://pubmed.ncbi.nlm.nih.gov/24377754

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Co-amplification of the HER2 gene and chromosome 17 centromere: a potential diagnostic pitfall in HER2 testing in breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/24377754

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Implementation of American Society of Clinical Oncology/College of American Pathologists HER2 Guideline Recommendations in a tertiary care facility increases HER2 immunohistochemistry and fluorescence in situ hybridization concordance and decreases

1 reference

https://pubmed.ncbi.nlm.nih.gov/24377754

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

High concordance between immunohistochemistry and fluorescence in situ hybridization testing for HER2 status in breast cancer requires a normalized IHC scoring system

1 reference

https://pubmed.ncbi.nlm.nih.gov/24377754

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Characteristics of HER2-positive breast cancer diagnosed following the introduction of universal HER2 testing

1 reference

https://pubmed.ncbi.nlm.nih.gov/24377754

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1186/1471-2407-13-615

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

Dimensions Publication ID

0 references

PMC publication ID

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q35078787&oldid=1954090126"